Audrey Sternberg

Articles

MET, RET, and TRK Inhibitors Achieve Standard-of-Care Status in Lung Cancer

November 9th 2020

Alterations in MET, RET, and NTRK have become established actionable drivers of oncogenesis in lung cancer, and therapeutics targeting these aberrations have since obtained regulatory approval from the FDA and have been incorporated into treatment guidelines.

COVID-19 Shines Light on Disparities in Care for Patients With Cancer

October 5th 2020

Findings have shown that patients with cancer are at an increased risk of developing severe illness due to coronavirus disease 2019.

DART Molecule MGD019 Displays Monotherapy Efficacy in Heavily Pretreated Solid Tumors

September 20th 2020

An acceptable safety profile coupled with pharmacokinetic and pharmacodynamic data for the DART molecule MGD019 were reported during the European Society for Medical Oncology Virtual Congress 2020 from results of a first-in-human study.

First-in-Human Study of RO7122290 Shows Promise in Patients With Select Solid Tumors

September 19th 2020

Safety and preliminary antitumor activity with the bispecific antibody RO7122290 alone or in combination with atezolizumab demonstrated preliminary antitumor activity and was safe for the treatment of patients with advanced solid tumors.

Tumor Regression Is Observed With Neoadjuvant Atezolizumab in Resectable NSCLC

September 19th 2020

One preoperative injection of atezolizumab was considered safe and induced major pathological responses in select patients with resectable non–small cell lung cancer.

Experts Consider Long-Term Impact of COVID-19 Pandemic on Oncology Care

September 13th 2020

As the impact of the coronavirus disease 2019 pandemic lingers into the later part of 2020, consideration is needed regarding the lasting effects on patients with cancer who may have experienced delayed care or diagnosis.

Cabozantinib Maintains Efficacy in Advanced RCC Irrespective of Prior Treatment

May 31st 2020

Patients with advanced renal cell carcinoma who were treated with cabozantinib (Cabometyx) following both immunotherapy and non-IO regimens demonstrated promising responses.

Updated AVANOVA2 Survival Data Further Support Niraparib Plus Bevacizumab in Recurrent Ovarian Cancer

May 30th 2020

Clinical outcomes in patients with recurrent ovarian cancer who were treated with niraparib plus bevacizumab were significantly improved when compared with niraparib alone.

Novel Anti-TIGIT Agent Tiragolumab Plus Atezolizumab Impresses in NSCLC

May 29th 2020

Patients with chemotherapy-naïve, locally advanced or metastatic non–small cell lung cancer who were treated in the phase 2 CITYSCAPE trial with tiragolumab, an inhibitor of the immunomodulatory receptor TIGIT, plus and anti–PD-L1 agent demonstrated better efficacy versus single-agent checkpoint inhibitor therapy alone.

Universal Allogeneic CAR T-Cell Product Demonstrates Efficacy in a Cohort of Adult T-ALL

April 29th 2020

The first-in-clinic universal CAR T-cell therapy TruUCAR GC027 induced promising early response rates and demonstrated a manageable safety profile with no evidence of neurotoxicity events or graft-versus-host disease in adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia.

Poziotinib Shows Mixed Findings in Exon 20-Mutant NSCLC

April 28th 2020

Patients with pretreated non–small cell lung cancer and EGFR exon 20 insertions demonstrated a 68.7% disease control rate while on poziotinib systemic therapy.

Immunotherapy Biomarker Testing Depends on Tumor Type

April 1st 2020

A Working Group of the European Society for Medical Oncology has determined that a decision tree on the sequential use of different tests in immunotherapy decision-making cannot be a general one for all cancers but should be designed on the basis of the specific tumor type.

Expanded Choices Emerge for Myelofibrosis Following Ruxolitinib Therapy

February 29th 2020

Newly approved and investigational agents are joining ruxolitinib for the treatment of myelofibrosis and may provide options for patients who progress or become intolerant to frontline JAK inhibitors.

KD025 Induces Impressive Activity in cGVHD

February 25th 2020

The selective ROCK2 inhibitor KD025 induced clinical responses in approximately two-thirds of patients with chronic graft-versus-host disease, including complete responses in 3 patients.

Narsoplimab Emerging as Treatment Option for TA-TMA

February 23rd 2020

Narsoplimab (OMS721) is advancing through the therapy pipeline as a novel treatment option for patients with transplant-associated thrombotic microangiopathy.

"Off-the-Shelf" CAR T-Cell Therapy Shows Promise in Non-Hodgkin Lymphoma

February 22nd 2020

An “off-the-shelf” Epstein Barr-virus–specific cytotoxic lymphocyte CAR product derived from cells harvested from third-party donors induced a 100% response rate in adult and pediatric patients with relapsed/refractory non-Hodgkin lymphoma.

Axi-Cel Toxicity in LBCL May Be Alleviated With Earlier Steroid Use

February 22nd 2020

Early steroid intervention has the potential to reduce the severity of adverse events associated with axicabtagene ciloleucel in patients with refractory large B-cell lymphoma, according to an analysis of the phase I/II ZUMA-1 trial.

Conditioning Therapy With Iomab-B Leads to High Transplant Rate in Active AML

February 21st 2020

Iodine (131I) apamistamab (Iomab-B) conditioning induced a complete remission in 84% (31/38) of patients with active acute myeloid leukemia, who were then able to receive allogeneic hematopoietic stem cell transplant, according to preliminary results from the phase III SIERRA trial.

Ruxolitinib Efficacy in Chronic GVHD Highlighted Across Age Groups

February 21st 2020

Ruxolitinib is an effective and well-tolerated treatment in the refractory setting for patients with chronic graft-versus-host disease, regardless of age.

Liso-Cel Analysis Shows Feasibility of Outpatient CAR T-Cell Therapy

February 20th 2020

Outpatient administration of CAR T-Cell therapy is safe and effective, according to an analysis of 3 studies of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.